Estimating the costs of genomic sequencing in cancer control.
Louisa G GordonNicole M WhiteThomas M ElliottKatia NonesAnthony G BeckhouseAstrid J Rodriguez-AcevedoPenelope M WebbXing J LeeNicholas GravesDeborah J SchofieldPublished in: BMC health services research (2020)
Total costs were most sensitive to consumables and sequencing activities driven by commercial prices. Per person sequencing costs for cancer are high when tumour/blood pairs require testing. Using the natural steps involved in sequencing and categorising resources accordingly, future evaluations of costs or cost-effectiveness of clinical genomics across cancer projects could be more standardised and facilitate easier comparison of cost drivers.